Randomized Phase 2 Study Evaluating the Interest of Mid-position Strategy Versus ITV (Internal Target Volume) Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-resected Non-small Cell Lung Carcinoma (NSCLC).
Inclusion Criteria:
- patient with a NSCLC, non-resected, non-metastatic including a parenchyma portion
- Age >= 18 years
- PS <=2
- CT-scan within 3 months at inclusion
- PET-scan within 3 months at inclusion
- Respiratory functional exploration within 3 months at inclusion
- estimated V20 (by radiotherapist)< 35% on conventional pre-radiotherapy imaging
- Tumor T1 to T4, M0; N1, N2 ou N3 by isolateral supra-clavicular involvement
- Measurable disease according to RECIST criteria 1.1
- Curative intent Chest conventional radiation therapy
- Radiation indication validated by a multidisciplinary meeting
- Adequate contraceptive method for the whole study duration and for up to 28 days
after the end of radiation
- Mandatory affiliation with a health insurance company
- Patients must provide dated & written consent
Exclusion Criteria:
- Prior surgery for NSCLC
- NSCLC nearby pulmonary apex or strictly intra-thoracic with no intra-parenchyma
portion
- Metastatic disease or N3 contralateral lymph node
- History of chest irradiation
- History of known increased intrinsic radiosensibility
- Hypersensibility to active substance or excipient of fluoro-deoxyglucose-18F
- Life expectancy < 6 months
- Patient with a concurrent malignancy or with a history of malignancy (excepted
adequately treated basal cell skin carcinoma or cervical squamous cell carcinoma or
other malignancies free of the disease for at least 5 years)
- Pregnant or breastfeeding women
- Psychological, sociological or geographical conditions that would limit compliance
with study requirements
- Patient deprived of freedom
- Patient has concomitant participation to an other investigational study